Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Scientists document a death from a meat allergy tied to certain ticks - 2The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- 3Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- 4Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
- 5These Are the Journalists Israel Has Killed Since the Start of the Iran War
- Wonderful Sea shores All over the Planet
- IDF finds weapon of slain hostage Capt. Daniel Perez in booby-trapped Gaza compound
- Well known SUVs With Low Energy Utilization In 2024
- ‘Harry Potter and the Philosopher’s Stone’ trailer is raising eyebrows among Potterheads: ‘Where’s the whimsical color?’
- How to watch the last supermoon of the year
- The Best Games On the planet
- Are protests pushing Iran's Islamic regime toward a tipping point?
- 'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
- Instructions to Pick the Right Tires for Your Slam 1500.
